CN107574149B - 一种树突状细胞的促成熟方法及其用途 - Google Patents
一种树突状细胞的促成熟方法及其用途 Download PDFInfo
- Publication number
- CN107574149B CN107574149B CN201610522851.1A CN201610522851A CN107574149B CN 107574149 B CN107574149 B CN 107574149B CN 201610522851 A CN201610522851 A CN 201610522851A CN 107574149 B CN107574149 B CN 107574149B
- Authority
- CN
- China
- Prior art keywords
- culture solution
- composition
- cells
- concentration
- ifn
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 210000004443 dendritic cell Anatomy 0.000 title claims abstract description 51
- 230000035800 maturation Effects 0.000 title claims abstract description 24
- 238000000034 method Methods 0.000 title claims abstract description 24
- 230000001737 promoting effect Effects 0.000 title claims abstract description 14
- 239000000203 mixture Substances 0.000 claims abstract description 95
- 229940115272 polyinosinic:polycytidylic acid Drugs 0.000 claims abstract description 69
- 102100035793 CD83 antigen Human genes 0.000 claims abstract description 39
- 101000946856 Homo sapiens CD83 antigen Proteins 0.000 claims abstract description 39
- 101000914484 Homo sapiens T-lymphocyte activation antigen CD80 Proteins 0.000 claims abstract description 37
- 102100027222 T-lymphocyte activation antigen CD80 Human genes 0.000 claims abstract description 37
- 108010065805 Interleukin-12 Proteins 0.000 claims abstract description 36
- 102000013462 Interleukin-12 Human genes 0.000 claims abstract description 36
- 210000001744 T-lymphocyte Anatomy 0.000 claims abstract description 33
- 206010028980 Neoplasm Diseases 0.000 claims abstract description 15
- 230000004936 stimulating effect Effects 0.000 claims abstract description 15
- 230000004913 activation Effects 0.000 claims abstract description 10
- 210000004027 cell Anatomy 0.000 claims description 119
- 108010074328 Interferon-gamma Proteins 0.000 claims description 49
- 102100037850 Interferon gamma Human genes 0.000 claims description 47
- 108090000978 Interleukin-4 Proteins 0.000 claims description 31
- 230000000638 stimulation Effects 0.000 claims description 28
- 239000000427 antigen Substances 0.000 claims description 24
- 108091007433 antigens Proteins 0.000 claims description 24
- 102000036639 antigens Human genes 0.000 claims description 24
- 102000004457 Granulocyte-Macrophage Colony-Stimulating Factor Human genes 0.000 claims description 22
- 108010017213 Granulocyte-Macrophage Colony-Stimulating Factor Proteins 0.000 claims description 22
- 230000001939 inductive effect Effects 0.000 claims description 15
- 210000003819 peripheral blood mononuclear cell Anatomy 0.000 claims description 10
- 238000002360 preparation method Methods 0.000 claims description 10
- 210000004881 tumor cell Anatomy 0.000 claims description 7
- 239000012531 culture fluid Substances 0.000 claims description 5
- 230000001464 adherent effect Effects 0.000 claims description 4
- 238000011534 incubation Methods 0.000 claims description 4
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 4
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 4
- 239000013592 cell lysate Substances 0.000 claims description 3
- 229940029030 dendritic cell vaccine Drugs 0.000 claims description 3
- 229920001184 polypeptide Polymers 0.000 claims description 3
- 239000013598 vector Substances 0.000 claims description 3
- 239000012930 cell culture fluid Substances 0.000 claims description 2
- 239000003814 drug Substances 0.000 claims description 2
- 102000040650 (ribonucleotides)n+m Human genes 0.000 claims 1
- 230000000694 effects Effects 0.000 abstract description 8
- 201000011510 cancer Diseases 0.000 abstract description 3
- 238000012258 culturing Methods 0.000 abstract description 3
- 230000009286 beneficial effect Effects 0.000 abstract 1
- 230000028327 secretion Effects 0.000 description 21
- 239000001963 growth medium Substances 0.000 description 17
- 102000002689 Toll-like receptor Human genes 0.000 description 16
- 108020000411 Toll-like receptor Proteins 0.000 description 16
- 239000000243 solution Substances 0.000 description 15
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 13
- 102100040247 Tumor necrosis factor Human genes 0.000 description 13
- MZOFCQQQCNRIBI-VMXHOPILSA-N (3s)-4-[[(2s)-1-[[(2s)-1-[[(1s)-1-carboxy-2-hydroxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-3-[[2-[[(2s)-2,6-diaminohexanoyl]amino]acetyl]amino]-4-oxobutanoic acid Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@@H](N)CCCCN MZOFCQQQCNRIBI-VMXHOPILSA-N 0.000 description 11
- 229940044601 receptor agonist Drugs 0.000 description 11
- 239000000018 receptor agonist Substances 0.000 description 11
- 238000004113 cell culture Methods 0.000 description 10
- 230000028993 immune response Effects 0.000 description 7
- 229920006395 saturated elastomer Polymers 0.000 description 7
- 230000011748 cell maturation Effects 0.000 description 6
- 239000003446 ligand Substances 0.000 description 6
- 239000006228 supernatant Substances 0.000 description 6
- 102000004127 Cytokines Human genes 0.000 description 5
- 108090000695 Cytokines Proteins 0.000 description 5
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 4
- 102000008235 Toll-Like Receptor 9 Human genes 0.000 description 4
- 108010060818 Toll-Like Receptor 9 Proteins 0.000 description 4
- 230000005856 abnormality Effects 0.000 description 4
- 239000006143 cell culture medium Substances 0.000 description 4
- 238000002474 experimental method Methods 0.000 description 4
- 230000001900 immune effect Effects 0.000 description 4
- 239000007788 liquid Substances 0.000 description 4
- 238000002965 ELISA Methods 0.000 description 3
- 230000005975 antitumor immune response Effects 0.000 description 3
- 210000003719 b-lymphocyte Anatomy 0.000 description 3
- 230000010261 cell growth Effects 0.000 description 3
- 238000003501 co-culture Methods 0.000 description 3
- 238000001514 detection method Methods 0.000 description 3
- 230000012010 growth Effects 0.000 description 3
- 210000002865 immune cell Anatomy 0.000 description 3
- 230000005847 immunogenicity Effects 0.000 description 3
- 238000000338 in vitro Methods 0.000 description 3
- 230000003834 intracellular effect Effects 0.000 description 3
- 230000003287 optical effect Effects 0.000 description 3
- 210000005259 peripheral blood Anatomy 0.000 description 3
- 239000011886 peripheral blood Substances 0.000 description 3
- 108090000623 proteins and genes Proteins 0.000 description 3
- GOZMBJCYMQQACI-UHFFFAOYSA-N 6,7-dimethyl-3-[[methyl-[2-[methyl-[[1-[3-(trifluoromethyl)phenyl]indol-3-yl]methyl]amino]ethyl]amino]methyl]chromen-4-one;dihydrochloride Chemical compound Cl.Cl.C=1OC2=CC(C)=C(C)C=C2C(=O)C=1CN(C)CCN(C)CC(C1=CC=CC=C11)=CN1C1=CC=CC(C(F)(F)F)=C1 GOZMBJCYMQQACI-UHFFFAOYSA-N 0.000 description 2
- 101000669402 Homo sapiens Toll-like receptor 7 Proteins 0.000 description 2
- 108010002350 Interleukin-2 Proteins 0.000 description 2
- 102100039390 Toll-like receptor 7 Human genes 0.000 description 2
- 230000003213 activating effect Effects 0.000 description 2
- 230000000259 anti-tumor effect Effects 0.000 description 2
- 210000000612 antigen-presenting cell Anatomy 0.000 description 2
- 210000001772 blood platelet Anatomy 0.000 description 2
- 230000024245 cell differentiation Effects 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- 238000007796 conventional method Methods 0.000 description 2
- 238000001816 cooling Methods 0.000 description 2
- 210000003743 erythrocyte Anatomy 0.000 description 2
- 238000000684 flow cytometry Methods 0.000 description 2
- 239000000568 immunological adjuvant Substances 0.000 description 2
- 230000001976 improved effect Effects 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 239000002609 medium Substances 0.000 description 2
- 229910052757 nitrogen Inorganic materials 0.000 description 2
- 230000001717 pathogenic effect Effects 0.000 description 2
- 230000001105 regulatory effect Effects 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- 229960005486 vaccine Drugs 0.000 description 2
- 238000005406 washing Methods 0.000 description 2
- 208000035404 Autolysis Diseases 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 102000018348 CC chemokine receptor 5 Human genes 0.000 description 1
- 102000011400 CC chemokine receptor 7 Human genes 0.000 description 1
- 108010017088 CCR5 Receptors Proteins 0.000 description 1
- 108010017158 CCR7 Receptors Proteins 0.000 description 1
- 210000001266 CD8-positive T-lymphocyte Anatomy 0.000 description 1
- 108010021064 CTLA-4 Antigen Proteins 0.000 description 1
- 102000008203 CTLA-4 Antigen Human genes 0.000 description 1
- 229940045513 CTLA4 antagonist Drugs 0.000 description 1
- 102000012000 CXCR4 Receptors Human genes 0.000 description 1
- 108010061299 CXCR4 Receptors Proteins 0.000 description 1
- 102000000844 Cell Surface Receptors Human genes 0.000 description 1
- 108010001857 Cell Surface Receptors Proteins 0.000 description 1
- 206010057248 Cell death Diseases 0.000 description 1
- 229930183912 Cytidylic acid Natural products 0.000 description 1
- 108700020359 Drosophila Tl Proteins 0.000 description 1
- 102000006354 HLA-DR Antigens Human genes 0.000 description 1
- 108010058597 HLA-DR Antigens Proteins 0.000 description 1
- 101001117317 Homo sapiens Programmed cell death 1 ligand 1 Proteins 0.000 description 1
- 101000831496 Homo sapiens Toll-like receptor 3 Proteins 0.000 description 1
- 101000800483 Homo sapiens Toll-like receptor 8 Proteins 0.000 description 1
- 108091008036 Immune checkpoint proteins Proteins 0.000 description 1
- 102000037982 Immune checkpoint proteins Human genes 0.000 description 1
- 102000043129 MHC class I family Human genes 0.000 description 1
- 108091054437 MHC class I family Proteins 0.000 description 1
- 206010057249 Phagocytosis Diseases 0.000 description 1
- 102100024216 Programmed cell death 1 ligand 1 Human genes 0.000 description 1
- 239000012980 RPMI-1640 medium Substances 0.000 description 1
- 108091008874 T cell receptors Proteins 0.000 description 1
- 229940123384 Toll-like receptor (TLR) agonist Drugs 0.000 description 1
- 102000008230 Toll-like receptor 3 Human genes 0.000 description 1
- 102100024324 Toll-like receptor 3 Human genes 0.000 description 1
- 108010060885 Toll-like receptor 3 Proteins 0.000 description 1
- 102100033110 Toll-like receptor 8 Human genes 0.000 description 1
- 102100034593 Tripartite motif-containing protein 26 Human genes 0.000 description 1
- GLNADSQYFUSGOU-GPTZEZBUSA-J Trypan blue Chemical compound [Na+].[Na+].[Na+].[Na+].C1=C(S([O-])(=O)=O)C=C2C=C(S([O-])(=O)=O)C(/N=N/C3=CC=C(C=C3C)C=3C=C(C(=CC=3)\N=N\C=3C(=CC4=CC(=CC(N)=C4C=3O)S([O-])(=O)=O)S([O-])(=O)=O)C)=C(O)C2=C1N GLNADSQYFUSGOU-GPTZEZBUSA-J 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 230000033289 adaptive immune response Effects 0.000 description 1
- 230000004721 adaptive immunity Effects 0.000 description 1
- 239000000556 agonist Substances 0.000 description 1
- 230000000890 antigenic effect Effects 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 238000001815 biotherapy Methods 0.000 description 1
- 230000000711 cancerogenic effect Effects 0.000 description 1
- 231100000315 carcinogenic Toxicity 0.000 description 1
- 239000006285 cell suspension Substances 0.000 description 1
- 238000002659 cell therapy Methods 0.000 description 1
- 230000003833 cell viability Effects 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 230000007969 cellular immunity Effects 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 230000000139 costimulatory effect Effects 0.000 description 1
- IERHLVCPSMICTF-XVFCMESISA-N cytidine 5'-monophosphate Chemical compound O=C1N=C(N)C=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](COP(O)(O)=O)O1 IERHLVCPSMICTF-XVFCMESISA-N 0.000 description 1
- IERHLVCPSMICTF-UHFFFAOYSA-N cytidine monophosphate Natural products O=C1N=C(N)C=CN1C1C(O)C(O)C(COP(O)(O)=O)O1 IERHLVCPSMICTF-UHFFFAOYSA-N 0.000 description 1
- 230000009089 cytolysis Effects 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 239000012636 effector Substances 0.000 description 1
- 210000001163 endosome Anatomy 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 230000017188 evasion or tolerance of host immune response Effects 0.000 description 1
- 210000003746 feather Anatomy 0.000 description 1
- 238000007710 freezing Methods 0.000 description 1
- 230000008014 freezing Effects 0.000 description 1
- 239000012595 freezing medium Substances 0.000 description 1
- 230000007849 functional defect Effects 0.000 description 1
- 238000003306 harvesting Methods 0.000 description 1
- 230000028996 humoral immune response Effects 0.000 description 1
- 230000036737 immune function Effects 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 230000003308 immunostimulating effect Effects 0.000 description 1
- 238000009169 immunotherapy Methods 0.000 description 1
- 230000015788 innate immune response Effects 0.000 description 1
- 230000010354 integration Effects 0.000 description 1
- 239000002799 interferon inducing agent Substances 0.000 description 1
- 230000002045 lasting effect Effects 0.000 description 1
- 201000007270 liver cancer Diseases 0.000 description 1
- 208000014018 liver neoplasm Diseases 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 210000004698 lymphocyte Anatomy 0.000 description 1
- 210000003712 lysosome Anatomy 0.000 description 1
- 230000001868 lysosomic effect Effects 0.000 description 1
- 210000002540 macrophage Anatomy 0.000 description 1
- 239000003550 marker Substances 0.000 description 1
- 239000002207 metabolite Substances 0.000 description 1
- 230000000813 microbial effect Effects 0.000 description 1
- 238000000386 microscopy Methods 0.000 description 1
- 230000005012 migration Effects 0.000 description 1
- 238000013508 migration Methods 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 230000035772 mutation Effects 0.000 description 1
- 230000004719 natural immunity Effects 0.000 description 1
- 108020004707 nucleic acids Proteins 0.000 description 1
- 102000039446 nucleic acids Human genes 0.000 description 1
- 150000007523 nucleic acids Chemical class 0.000 description 1
- 238000005457 optimization Methods 0.000 description 1
- 244000052769 pathogen Species 0.000 description 1
- 239000008188 pellet Substances 0.000 description 1
- 230000008782 phagocytosis Effects 0.000 description 1
- 239000008194 pharmaceutical composition Substances 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 102000005962 receptors Human genes 0.000 description 1
- 108020003175 receptors Proteins 0.000 description 1
- 230000028043 self proteolysis Effects 0.000 description 1
- 230000011664 signaling Effects 0.000 description 1
- 239000012192 staining solution Substances 0.000 description 1
- 239000011550 stock solution Substances 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- 230000002195 synergetic effect Effects 0.000 description 1
- 230000009258 tissue cross reactivity Effects 0.000 description 1
- 239000003970 toll like receptor agonist Substances 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 238000001890 transfection Methods 0.000 description 1
- 230000004565 tumor cell growth Effects 0.000 description 1
- 241000701161 unidentified adenovirus Species 0.000 description 1
- 230000003827 upregulation Effects 0.000 description 1
Images
Abstract
Description
Claims (53)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201610522851.1A CN107574149B (zh) | 2016-07-05 | 2016-07-05 | 一种树突状细胞的促成熟方法及其用途 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201610522851.1A CN107574149B (zh) | 2016-07-05 | 2016-07-05 | 一种树突状细胞的促成熟方法及其用途 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN107574149A CN107574149A (zh) | 2018-01-12 |
CN107574149B true CN107574149B (zh) | 2022-02-18 |
Family
ID=61049951
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201610522851.1A Active CN107574149B (zh) | 2016-07-05 | 2016-07-05 | 一种树突状细胞的促成熟方法及其用途 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN107574149B (zh) |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN111733129A (zh) * | 2020-04-02 | 2020-10-02 | 成都源泉生物科技有限公司 | 一种聚肌胞诱导的高效dc-cik细胞的方法 |
CN111500537A (zh) * | 2020-05-06 | 2020-08-07 | 天津纽赛生物技术有限公司 | 一种脂肪酸促进树突状细胞成熟及增强其功能方法及应用 |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2011098516A1 (en) * | 2010-02-10 | 2011-08-18 | Immunicum Ab | Improved composition for inhibiting tumor cell proliferation |
CN103566377A (zh) * | 2012-07-18 | 2014-02-12 | 上海博笛生物科技有限公司 | 癌症的靶向免疫治疗 |
CN105440135A (zh) * | 2014-09-01 | 2016-03-30 | 博笛生物科技有限公司 | 用于***的抗-pd-l1结合物 |
CN105462926A (zh) * | 2015-12-31 | 2016-04-06 | 深圳市中美康士生物科技有限公司 | 一种免疫细胞瘤苗的制备方法及其应用 |
-
2016
- 2016-07-05 CN CN201610522851.1A patent/CN107574149B/zh active Active
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2011098516A1 (en) * | 2010-02-10 | 2011-08-18 | Immunicum Ab | Improved composition for inhibiting tumor cell proliferation |
CN103566377A (zh) * | 2012-07-18 | 2014-02-12 | 上海博笛生物科技有限公司 | 癌症的靶向免疫治疗 |
CN105440135A (zh) * | 2014-09-01 | 2016-03-30 | 博笛生物科技有限公司 | 用于***的抗-pd-l1结合物 |
CN105462926A (zh) * | 2015-12-31 | 2016-04-06 | 深圳市中美康士生物科技有限公司 | 一种免疫细胞瘤苗的制备方法及其应用 |
Non-Patent Citations (4)
Title |
---|
Differential induction of inflammatory cytokines by dendritic cells treated with novel TLR-agonist and cytokine based cocktails: targeting dendritic cells in autoimmunity;Simon S Jensen et al.,;《Inflammation》;20101231;第7卷(第37期);第3页右栏最后一段,第4页右栏最后一段,表1,图1 * |
Extracellular ATP Induces a Distorted Maturation of Dendritic Cells and Inhibits Their Capacity to Initiate Th1 Responses;Andrea la Sala et al.,;《Immunology》;20011231;第166卷;摘要 * |
R848 联合Poly(I:C)促进DC抗原呈递和增强T细胞杀伤效果的研究;黄雪等;《中国病理生理杂志》;20181231;第34卷(第4期);第611-616页 * |
不同方式负载AFP抗原的DC诱导抗肝癌HepG2细胞免疫效应的比较;李洁羽等;《中国肿瘤生物治疗杂志》;20151031;第22卷(第5期);摘要 * |
Also Published As
Publication number | Publication date |
---|---|
CN107574149A (zh) | 2018-01-12 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP4610847B2 (ja) | すぐ使用できる、抗原負荷また非負荷の凍結保存された成熟成樹状細胞の調製方法 | |
JP2021045176A (ja) | 未成熟な単球性樹状細胞の活性化を誘導するための組成物および方法 | |
EP1441591B1 (en) | Compositions and methods for priming monocytic dendritic cells and t cells for th-1 response | |
JP2009518045A5 (zh) | ||
PL209998B1 (pl) | Sposób in vitro lub ex vivo różnicowania monocytarnych prekursorów komórek dendrytycznych w niedojrzale komórki dendrytyczne | |
CN107574149B (zh) | 一种树突状细胞的促成熟方法及其用途 | |
AU2011260606B2 (en) | Novel interferon-alpha-producing bone marrow dendritic cells | |
CN111166876B (zh) | 一种免疫增强剂组合和编码核酸及其应用 | |
KR101440102B1 (ko) | 하이드로젤 코팅과 전기천공법을 이용한 강력한 항원제시세포의 제조방법 | |
WO2019243537A1 (en) | Method for the in vitro differentiation and maturation of dendritic cells for therapeutic use | |
US20230348856A1 (en) | Pharmaceutical composition, and preparation method therefor and application thereof | |
Jian et al. | Optimal conditions for adenoviral transduction of immature dendritic cells without affecting the tolerogenic activity of DC-based immunotherapy | |
AU2013206016B2 (en) | Compositions and methods for inducing the activation of immature monocytic dendritic cells | |
AU2013201707B2 (en) | Compositions and methods for priming monocytic dendritic cells and T cells for Th-1 response | |
AU2002326846A1 (en) | Compositions and methods for priming monocytic dendritic cells and T cells for Th-1 response |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
CB02 | Change of applicant information |
Address after: No. 1585 Yuanguo Road, Jiading District, Shanghai, 201805 Applicant after: SHANGHAI CELL THERAPY Research Institute Applicant after: SHANGHAI CELL THERAPY GROUP Co.,Ltd. Address before: No. 1585 Yuanguo Road, Jiading District, Shanghai, 201805 Applicant before: Shanghai cell therapy research institute Applicant before: SHANGHAI ENGINEERING RESEARCH CENTER FOR CELL THERAPY GROUP Co.,Ltd. |
|
CB02 | Change of applicant information | ||
GR01 | Patent grant | ||
GR01 | Patent grant | ||
CP03 | Change of name, title or address |
Address after: No. 1585 Yuanguo Road, Jiading District, Shanghai, 201805 Patentee after: SHANGHAI CELL THERAPY Research Institute Country or region after: China Patentee after: Shanghai Cell Therapy Group Co.,Ltd. Address before: No. 1585 Yuanguo Road, Jiading District, Shanghai, 201805 Patentee before: SHANGHAI CELL THERAPY Research Institute Country or region before: China Patentee before: SHANGHAI CELL THERAPY GROUP Co.,Ltd. |